skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

100+ Total results for product and free and sample content found

In Vivo

In Vivo Outlook 2021 Report

08 Oct 2021

In Vivo Outlook 2021 Report

The highly anticipated Outlook 2022 report from Informa Pharma Intelligence is coming soon. Reach the thousands of senior decision makers who eagerly await this pharma industry ranking and review for the year ahead, with sponsorship opportunities that align your brand with our trusted information. 

Topic Deals BioPharmaceutical Business Strategies

Biomedtracker, Datamonitor Healthcare

Key Potential Drug Launches in 2022

23 Sep 2021

Key Potential Drug Launches in 2022

Released July 22, 2021. Contains information like likelihood of approval (LOA) ratings and upcoming catalysts that are current as of April 2021.

Scrip

Scrip Asia 100

20 Sep 2021

Scrip Asia 100

The highly anticipated Scrip Asia 100 is back, and there are a limited number of opportunities for you to be a part of it. Don’t miss your chance to connect to APAC market leaders with a high-profile sponsorship of this essential annual financial performance ranking of pharma companies headquartered in the APAC region.

Topic Business Strategies

Thought leadership, Pharma Marketing Solution...

Putting Account-Based Marketing to work for your high-value clients

13 Sep 2021

Putting Account-Based Marketing to work for your high-value clients

Account-based marketing/engagement (ABM/ABE): this customer-centric, cross-functional approach to delivering clients and prospective clients superior marketing campaigns has become increasingly popular.

Topic Market Intelligence

Biomedtracker, Meddevicetracker

Q3 2021 Outlook Report

27 Aug 2021

Q3 2021 Outlook Report

What major drug catalysts and events can you expect to see in the months ahead? Download your free extract from the Q3 2021 Outlook Report and infographic to find out. Shape your strategy with your inside look at what’s to come.

Topic Drug Review

Pharma Consulting

ASGCT/Pharma Intelligence Quarterly Report: Q2 2021

20 Aug 2021

asgct-report-q2

We’re excited to share our latest Q2 report on Gene, Cell, & RNA Therapies with The American Society of Gene & Cell Therapy (ASGCT). This newest report calls out some important updates and changes within the Gene, Cell, & RNA Therapy Landscape.

Topic Cell & Gene Therapy

Datamonitor Healthcare, Biomedtracker, Scrip

2021 Post-ASCO Insights and Analysis

11 Aug 2021

post-asco-2021

The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.

Topic Cancer

Citeline Connect

Patient Perspectives on Clinical Trial Participation Report

22 Jul 2021

Patient Perspectives on Clinical Trial Participation Report

Informa Pharma Intelligence partnered with Rare Patient Voice to measure the pulse of the public in relation to clinical trial participation post-COVID-19

Topic Clinical Trials

Medtech Insight

Pre-MDR Predictions and What You Can Expect

07 Jun 2021

MDR Pre-Coverage Update

Updates to the EU Medical Devices Regulation are just weeks away from becoming a reality for manufacturers and suppliers. Medtech Insight delivers expert insights into the latest developments and what they could mean for your business.

Topic Medtech

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: